Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James C Paulson

Showing results (1-10 of 264) with videos related to

Pageof 27
Sort By:
Cell|August 28, 2007
Innate immune response triggers lupus-like autoimmune diseaseJames C Paulson
Nature Biotechnology|May 10, 2011
Sialidase inhibitors DAMPen sepsisJames C Paulson, Norihito Kawasaki
Nature Structural & Molecular Biology|November 6, 2009
Glycan terminatorJames C Paulson, Christoph Rademacher
Proteomics|April 17, 2007
Frontiers in glycomics; bioinformatics and biomarkers in disease. September 11-13, 2006 Natcher Conference Center, NIH Campus, Bethesda, MD, USANaoyuki Taniguchi, James C Paulson
ACS Chemical Biology|March 1, 2012
Glycan fingerprints: calculating diversity in glycan librariesChristoph Rademacher, James C Paulson
Journal of the American Chemical Society|August 23, 2017
CD22 Ligands on a Natural N-Glycan Scaffold Efficiently Deliver Toxins to B-Lymphoma CellsWenjie Peng, James C Paulson
Annual Review of Immunology|January 28, 2020
Siglecs as Immune Cell Checkpoints in DiseaseShiteng Duan, James C Paulson
Methods in Enzymology|September 7, 2010
Multivalent ligands for siglecsMary K O'Reilly, James C Paulson
Current Opinion in Chemical Biology|November 24, 2004
Cell surface biology mediated by low affinity multivalent protein-glycan interactionsBrian E Collins, James C Paulson
Trends in Pharmacological Sciences|April 11, 2009
Siglecs as targets for therapy in immune-cell-mediated diseaseMary K O'Reilly, James C Paulson
Pageof 27

Showing results (1-10 of 264) with videos related to

Sort By:
Pageof 27
Cell|August 28, 2007
Innate immune response triggers lupus-like autoimmune diseaseJames C Paulson
Nature Biotechnology|May 10, 2011
Sialidase inhibitors DAMPen sepsisJames C Paulson, Norihito Kawasaki
Nature Structural & Molecular Biology|November 6, 2009
Glycan terminatorJames C Paulson, Christoph Rademacher
Proteomics|April 17, 2007
Frontiers in glycomics; bioinformatics and biomarkers in disease. September 11-13, 2006 Natcher Conference Center, NIH Campus, Bethesda, MD, USANaoyuki Taniguchi, James C Paulson
ACS Chemical Biology|March 1, 2012
Glycan fingerprints: calculating diversity in glycan librariesChristoph Rademacher, James C Paulson
Journal of the American Chemical Society|August 23, 2017
CD22 Ligands on a Natural N-Glycan Scaffold Efficiently Deliver Toxins to B-Lymphoma CellsWenjie Peng, James C Paulson
Annual Review of Immunology|January 28, 2020
Siglecs as Immune Cell Checkpoints in DiseaseShiteng Duan, James C Paulson
Methods in Enzymology|September 7, 2010
Multivalent ligands for siglecsMary K O'Reilly, James C Paulson
Current Opinion in Chemical Biology|November 24, 2004
Cell surface biology mediated by low affinity multivalent protein-glycan interactionsBrian E Collins, James C Paulson
Trends in Pharmacological Sciences|April 11, 2009
Siglecs as targets for therapy in immune-cell-mediated diseaseMary K O'Reilly, James C Paulson
Pageof 27